patient management

Join me, Matthew Gillogly, for another episode of The Practice Profit System. 

In this episode, we dive into the fascinating world where medicine meets business, featuring the incredible journey of Dr. John Ferrell III.

Join us as we explore how Dr. John Ferrell III has seamlessly integrated cash-based procedures into his orthopedic practice, bringing substantial financial growth in just 60 days. We'll hear firsthand about his passion for regenerative medicine and the challenges he faced in introducing less invasive treatments like Platelet-Rich Plasma (PRP) to a surgery-focused medical community.

Discover the pivotal role business understanding plays in the success of a medical practice as he shares his experiences and insights. From the founding of his practice to navigating growth decisions and insurance strategies, we'll discuss the strategies that have propelled his practice forward.

Furthermore, learn about Dr. John Ferrell III's vision for the future of regenerative orthopedics, where evidence-based practices and education are paramount. Together, we'll explore how blending medical expertise with business acumen is essential for modern healthcare practices, especially in fields like regenerative medicine.

So, if you're ready to gain valuable insights into the intersection of medicine and business, join us for this exciting episode featuring Dr. John Ferrell III. 

HEOR Ltd. have been working on an exciting new framework called Total System Value™. This episode of tHEORetically speaking features their CEO Phil McEwan and CGO Jeff Anderson to talk to us about this dynamic approach to value demonstration.

Total System Value™ (TSV)™ is a new, dynamic framework designed to assess the value of adopting a new technology or policy initiative at a population level.

For more information or to access other resources, click here. 

With recent advancements in medical treatments for metastatic renal cell carcinoma (mRCC), increased treatment efficiency may also come with increased toxicity. In this podcast, authors discuss the appropriate management of the adverse events that result from drug toxicity in order to achieve optimal oncological outcomes for their patients whilst still maintaining their quality of life.

This podcast is published open access in Advances in Therapy and is fully citeable. You can access the original published podcast article through the Advances in Therapy website and by using this link: https://link.springer.com/article/10.1007/s12325-023-02571-5. All conflicts of interest can be found online.

This podcast has been developed through an educational grant from Eisai. The authors were selected by the journal, and the content of the podcast was developed independently by the authors and the journal Editor. The Rapid Service and Open Access Fees were also funded by the unrestricted educational grant from Eisai.

Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

Disclosures:

Ricardo Rendon
Advisory Board: Astellas, Amgen, Abbvie, Janssen, Bayer, AstraZeneca, Ferring, Sanofi
Speakers Bureau: Astellas, Amgen, Ferring, Janssen
Clinical Trials: Amgen, Astellas, Abbvie, Ferring, Janssen, AstraZeneca, Sanofi, Pfizer, Myovant